Promising clinical activities support combination immunotherapy for metastatic kidney cancer

The results of an open-label pilot study by researchers at The University of Texas MD Anderson Cancer Center in America comparing combinations of anti-PD1 (nivolumab) with either anti-CTLA-4 (ipilimumab) or anti-VEGF (bevacizumab) therapies, revealed “promising clinical activities” in people with metastatic renal cell carcinoma (mRCC). The results from the pilot study will be presented early […]

read more

Cabozantinib plus nivolumab phase 3 clinical trial in first-line kidney cancer

Exelixis and Bristol-Myers Squibb (BMS) have announced a clinical development collaboration for a programme, co-funded by each company, to evaluate a combination of cabozantinib (Cabometyx) plus nivolumab (Opdivo) as a first-line treatment for advanced renal cell carcinoma, either with or without ipilimumab (Yervoy). The development programme will include a phase 3 pivotal trial in first-line […]

read more

Phase I study shows promise with nivolumab and ipilimumab combination in kidney cancer

Results from the CheckMate-016 study to investigate a combination of nivolumab and ipilimumab in people with advanced renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) meeting in Copenhagen over the weekend. The results show that 40% of patients treated with the nivolumab/ipilimumab combination experienced a significant reduction in the […]

read more

Nivolumab plus ipilimumab combo approved by NICE for melanoma

The National Institute for Health and Care Excellence (NICE) has approved a combination of two immunotherapy drugs, nivolumab (Opdivo) and ipilimumab (Yervoy), for the treatment of advanced skin cancer (melanoma). This approval comes within a couple of months of the combination getting a licence. Patients with advanced melanoma in England and Wales will be the first […]

read more
Showing 51 to 54 of 54 results